Novel sirolimus-eluting scaffold system demonstrates ‘potential to address Achilles’ heel’ of currently available endovascular treatment options

Ongoing studies of the Efemoral vascular scaffold system (EVSS)—previously described as a potential new paradigm in the treatment of long occlusive lesions—show that the device continues to show promise, according to investigators. The latest animal study assessed the subacute response…
Breakthrough Device designation granted for Efemoral scaffold system designed to treat CLTI

Efemoral Medical has announced the granting of Food and Drug Administration (FDA) Breakthrough Device status for its novel Efemoral vascular scaffold system (EVSS) designed to treat de novo or restenotic lesions of the infrapopliteal arteries in patients with chronic limb-threatening ischemia (CLTI).…
Efemoral Medical closes financing round to fund ongoing study of its vascular scaffold system

Efemoral Medical has today announced the closing of its $4.9 million preferred Series A1 round. Supported by existing investors as well as an experienced cohort of new investors, the proceeds will further Efemoral’s device development and expand enrollment in its…
Potential ‘new paradigm’ in treatment of long occlusive lesions emerges

Vascular surgeon Lewis Schwartz, MD, has had an interest in biomedical engineering since very early in his career. So his involvement in the early-stage Efemoral vascular scaffold system marks a significant milestone in a mission to save legs and provide…

